210 related articles for article (PubMed ID: 12823911)
21. New treatment strategies in cystic fibrosis: rhDNase.
Shah PL; Hodson ME
Monaldi Arch Chest Dis; 1996 Apr; 51(2):125-9. PubMed ID: 8680379
[TBL] [Abstract][Full Text] [Related]
22. DNase in stable cystic fibrosis infants: a pilot study.
Berge MT; Wiel Ev; Tiddens HA; Merkus PJ; Hop WC; de Jongste JC
J Cyst Fibros; 2003 Dec; 2(4):183-8. PubMed ID: 15463871
[TBL] [Abstract][Full Text] [Related]
23. Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.
Eisenberg JD; Aitken ML; Dorkin HL; Harwood IR; Ramsey BW; Schidlow DV; Wilmott RW; Wohl ME; Fuchs HJ; Christiansen DH; Smith AL
J Pediatr; 1997 Jul; 131(1 Pt 1):118-24. PubMed ID: 9255202
[TBL] [Abstract][Full Text] [Related]
24. Characterization of aerosols of human recombinant deoxyribonuclease I (rhDNase) generated by jet nebulizers.
Cipolla D; Gonda I; Shire SJ
Pharm Res; 1994 Apr; 11(4):491-8. PubMed ID: 8058603
[TBL] [Abstract][Full Text] [Related]
25. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis.
Suri R; Metcalfe C; Wallis C; Bush A
Pediatr Pulmonol; 2004 Apr; 37(4):305-10. PubMed ID: 15022126
[TBL] [Abstract][Full Text] [Related]
26. [Clinical development of rhDNase in the United States].
Eisenberg J
Arch Pediatr; 1995 Jul; 2(7):674-8. PubMed ID: 7663659
[TBL] [Abstract][Full Text] [Related]
27. [Multicenter study of rhDNase in cystic fibrosis with severe pulmonary involvement].
Hodson M
Arch Pediatr; 1995 Jul; 2(7):679-81. PubMed ID: 7663660
[TBL] [Abstract][Full Text] [Related]
28. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial.
Bakker EM; Volpi S; Salonini E; Müllinger B; Kroneberg P; Bakker M; Hop WC; Assael BM; Tiddens HA
Pediatr Pulmonol; 2014 Feb; 49(2):154-61. PubMed ID: 23913868
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis.
Ranasinha C; Assoufi B; Shak S; Christiansen D; Fuchs H; Empey D; Geddes D; Hodson M
Lancet; 1993 Jul; 342(8865):199-202. PubMed ID: 8100928
[TBL] [Abstract][Full Text] [Related]
30. The timing of rhDNase in relation to airway clearance therapy-unplugged.
Tannenbaum EL; Ranganathan S
Pediatr Pulmonol; 2007 Dec; 42(12):1235; author reply 1236-7. PubMed ID: 17708574
[No Abstract] [Full Text] [Related]
31. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group.
Geller DE; Eigen H; Fiel SB; Clark A; Lamarre AP; Johnson CA; Konstan MW
Pediatr Pulmonol; 1998 Feb; 25(2):83-7. PubMed ID: 9516090
[TBL] [Abstract][Full Text] [Related]
32. Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis.
Frederiksen B; Pressler T; Hansen A; Koch C; Høiby N
Acta Paediatr; 2006 Sep; 95(9):1070-4. PubMed ID: 16938752
[TBL] [Abstract][Full Text] [Related]
33. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients.
Hansen G; Hoffjan S; Mosler K; Schuster A
Lung; 2001; 179(3):185-94. PubMed ID: 11891608
[TBL] [Abstract][Full Text] [Related]
34. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis.
Suri R; Wallis C; Bush A; Thompson S; Normand C; Flather M; Grieve R; Metcalfe C; Lees B
Health Technol Assess; 2002; 6(34):iii, 1-60. PubMed ID: 12583821
[No Abstract] [Full Text] [Related]
35. Impact of PEGylation on the mucolytic activity of recombinant human deoxyribonuclease I in cystic fibrosis sputum.
Guichard MJ; Kinoo D; Aubriot AS; Bauwens N; Gougué J; Vermeulen F; Lebecque P; Leal T; Vanbever R
Clin Sci (Lond); 2018 Jul; 132(13):1439-1452. PubMed ID: 29871879
[TBL] [Abstract][Full Text] [Related]
36. Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I.
Shah PL; Scott SF; Fuchs HJ; Geddes DM; Hodson ME
Thorax; 1995 Apr; 50(4):333-8. PubMed ID: 7785003
[TBL] [Abstract][Full Text] [Related]
37. Nebulization of PEGylated recombinant human deoxyribonuclease I using vibrating membrane nebulizers: A technical feasibility study.
Mahri S; Wilms T; Hagedorm P; Guichard MJ; Vanvarenberg K; Dumoulin M; Frijlink H; Vanbever R
Eur J Pharm Sci; 2023 Oct; 189():106522. PubMed ID: 37423579
[TBL] [Abstract][Full Text] [Related]
38. Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus.
Zahm JM; Girod de Bentzmann S; Deneuville E; Perrot-Minnot C; Dabadie A; Pennaforte F; Roussey M; Shak S; Puchelle E
Eur Respir J; 1995 Mar; 8(3):381-6. PubMed ID: 7789481
[TBL] [Abstract][Full Text] [Related]
39. Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis.
Sanders NN; Franckx H; De Boeck K; Haustraete J; De Smedt SC; Demeester J
Thorax; 2006 Nov; 61(11):962-8. PubMed ID: 17071834
[TBL] [Abstract][Full Text] [Related]
40. Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients.
Sawicki GS; Chou W; Raimundo K; Trzaskoma B; Konstan MW
J Cyst Fibros; 2015 Nov; 14(6):777-83. PubMed ID: 25921451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
